Press Releases

GENESIS Pharma has been awarded the DIAMOND highest distinction for its performance in sustainable development for 2024-2025, based on the international ESG criteria, in the National Corporate Responsibility Index (CR Index) of the Corporate Responsibility Institute. GENESIS Pharma was the first pharmaceutical company to participate in this assessment back in 2009, and has continuously improved its performance ever since. Its ranking at the highest level of the Index, an achievement reached by only seven companies to date, reflects the company’s comprehensive strategic approach and the successful integration of sustainable development principles across its operations.

GENESIS Pharma announces an exclusive distribution agreement with Santhera Pharmaceuticals (SIX: SANN) for vamorolone, indicated for the treatment of Duchenne muscular dystrophy (DMD), in 20 markets in Central and Eastern Europe. This strategic collaboration aims to address unmet medical needs by allowing GENESIS Pharma to commercialize vamorolone in Greece, Cyprus, Malta, Romania, Bulgaria, Slovenia, Croatia, Poland, Czech Republic, Hungary, Slovakia, Lithuania, Latvia, Estonia, Serbia, North Macedonia, Bosnia & Herzegovina, Montenegro, Albania, and Kosovo.

GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, have announced a commercialization agreement for two new orphan-designated medicines in Greece, Cyprus and Malta. Under the terms of the agreement, GENESIS Pharma will commercialize Burosumab for the treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO) and Mogamulizumab for two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma, upon local market approval.